

Elixirgen Scientific, Inc. Science + Technology Park at Johns Hopkins 855 N. Wolfe Street, Suite 631

Baltimore, MD 21205, USA

www.elixirgensci.com Email: cs@elixirgensci.com

Phone: +1-443-869-5420

License statement

All of the Elixirgen Scientific products are cleared with relevant external licenses. Please see below for the licensing situation for each product group. All of the products do not incur any license charge on end users for any type of use, except for the use in humans or for the therapeutic or diagnostic use.

Reagent kits for human pluripotent stem cell differentiation

Reagent kits to differentiate human pluripotent stem cells called Quick-Tissue™ Series do not require any additional license from other parties for any type of use, except for the use in humans or for the therapeutic or diagnostic use. All of the license statuses are shown below.

- Patents for differentiation methods are licensed from Keio University and Elixirgen, LLC
- Patents for the use of Sendai virus vectors are licensed from ID Pharma, Co., Ltd.

Differentiated cells from CIRM hPSC repository

The use of differentiated cells provided by Elixirgen Scientific do not require any additional license from other parties for any type of use, except for the use in humans or for the therapeutic or diagnostic use. Refer to the following notes.

- Elixirgen Scientific executed "<u>STANDARD LICENSE AGREEMENT FOR CIRM BANK IPS CELLS (small entity)</u>", which is public at the Coriell website (https://www.coriell.org/)
- This license enables Elixirgen Scientific to commercially distribute differentiated cells worldwide.
- Users do not need any additional license for the use of these differentiated cells even when cells are used for high throughput screening or drug discovery.
- All donor consents include statements on the following (FAQ section of this page):
 - Testing the cells' DNA (this is referred to as the cell's genetic code or sequence) and making the information known to other researchers
 - Changing some of the genetic code or sequence within these cells
 - Using cells to test or select drugs to treat disease
 - Transplanting cells or resulting products to humans or animals
 - Distributing cells widely (nationally and internationally) for research, training or commercial medical product development
 - Future research and uses unforeseen at this time
- Donors were screened and negative for HIV, HBV, and HCV. Donors under the age of 18 could opt out of HIV testing; all HCV-positive donors submitted skin punches, not peripheral blood, and were not screened for any infectious agents due to small volume of blood present in punches.
- Human induced pluripotent stem cells were established by non-integrating episomal reprogramming.
 Reprogramming and quality control were performed by Cellular Dynamics International.